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Introduction
Systemic lupus erythematosus (SLE) is a complex
autoimmune disease characterized by enhancement of
humoral and impaired cellular immune response.
Autoreactivity of the CD4+ T and B cells is suspected
to be responsible for abundant autoantibody produc-
tion directed against self antigens [1,2]. The excessive
production of autoantibodies causes immune complex
formation, which can be deposited in various tissues
resulting in dysfunction of organs and systems and
clinical manifestation of SLE [1,2]. 
Standard treatment of patients with SLE includes
reduction of lymphocyte autoreactivity with synthetic
glucocorticosteroids (GCs) or other immunosuppres-
sive agents [3-6]. Biological actions of GCs are medi-
ated by glucocorticoid receptor that is a member of
steroid/thyroid/retinoic acid receptor [3-6]. GCs and
receptor complex binds to DNA and regulates gene
transcription in a ligand-dependent manner. This leads
to a reduction of the cellular pool of NF-kappa B and
AP-1 transcription factors, and a decreased expression
of genes encoding proteins contributing to autoreactiv-
ity of the T and B cells [3-6]. 
The GR occurs mainly in two alternative splice
variants of nine exons encoding functional GRα and
nonfunctional GRβ. GRα and GRβ variants consist of
777 and 742 amino acids, respectively. They are iden-
tical from amino acid residue 1 to 727, and are distinct
only in the carboxyl terminal region. GRα contains an
additional 50 amino acids, encoding helices 11 and 12
to form a complete carboxy terminus ligand-binding
domain (LBD) [7,8]. However, GRβ does not contain
helix 12 of LBD but possesses a distinct amino acid
sequence in helix 11 compared to GRα (Fig. 1) [7,8].
The shorter LBD of GRβ is found constitutively in the
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nucleus and is not able to bind ligand or to mediate
anti-inflammatory GC effects [7]. Three mechanisms
responsible for negative activity of GRβ have been
proposed [7,8].  GRβ competes with GRα for binding
to GC response element of DNA,  GRβ and GRα form
non-transactivating heterodimers, or GRβ may also
bind limiting numbers of coactivators for GRα [7,8].
Glucocorticoid resistance due to an imbalance in
the GRα/GRβ ratio was found in various autoimmune
diseases [7,9]. However, the increased expression of
GRβ receptor in SLE patients was never determined. 
In our study, we compared the GRα and GRβ tran-
script and protein levels in peripheral blood mononu-
clear cells (PBMCs) from ten patients with low disease
activity and two patients who exhibited high disease
activity, both groups confirmed as SLE patients.
Materials and methods 
Patients. Twelve patients fulfilling the American College of
Rheumatology Classification criteria for SLE were randomly cho-
sen for this study at the Institute of Rheumatology in Warsaw,
Poland (Table 1) [1,2]. All patients were orally treated with methyl-
prednisolone >0.5 mg/kg/day. Two of them, with the most active
disease according to scoring calculated by Systemic Lupus Erythe-
matosus Disease Activity Index (SLEDAI) (Table 1) received as
much as 4 mg/kg/day of methylprednisolone over 3 days, and
intravenous pulses of cyclophosphamide. The protocol of the study
was approved by the Local Ethical Committee. Written informed
consent was obtained from all participating subjects. Patients were
asked not to take any medication for at least 24 h before drawing
the blood. Blood samples were collected with EDTA-based blood
sampling syringes Monovette (Sarstedt, Stare Babice, Poland).
Antibodies. Rabbit polyclonal anti-GRα antibodies (Ab)
(ab3580), rabbit polyclonal IgG anti-GRβ Ab (ab3581) were pur-
chased from Abcam (Cambridge, MA). Goat anti-rabbit horserad-
ish peroxidase (HRP)-conjugated antibodies (Ab) and goat poly-
clonal anti-actin HRP-conjugated Ab (clone I-19) were provided
by Santa Cruz Biotechnology (Santa Cruz, CA). 
Real-time quantitative PCR (RQ-PCR) analysis of GRα and
GRβ transcript level in PBMCs. The PMBCs were isolated from
venous whole blood by centrifugation over Ficoll-Hypaque
(d=1.077 g/cm3). Total RNA was isolated according to the method
of Chomczynski and Sacchi [10]. RNA samples were treated with
DNase I, quantified, and reverse-transcribed into cDNA. Quantita-
tive analysis of GRα and GRβ cDNA was performed by RQ-PCR
SYBR Green I system with Light Cycler, Roche Diagnostics
GmbH, (Mannheim, Germany). The quantity of GR variant tran-
scripts in each sample was normalized with polymerase II
(POLR2A) transcript level. The GRα, GRβ, and POLR2A cDNA
were amplified employing pairs of primers: (5'TCA ACT GAC
AAA ACT CTT GG3'), (5'TGA TTG GTG ATG ATT TCA GC3'),
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Fig. 1. Diagram of GR gene map and composition of GRα and GRβ transcript isoforms. Boxes and dashed lines represent exons and
introns, respectively. Exons are numbered at the middle of the corresponding box. The exons 1a, 1b and 1c correspond to multiple pro-
moters leading to transcription of several GR mRNAs with unique 5'-untranslated region in exon 1. The black areas of exons 2 to 9 include
an open reading frame. The white boxes correspond to 5'-untranslated and 3'-untranslated regions. Alternative processing of the GR pri-
mary transcript at exon 9 generates GRα and GRβ splice variants, which differ by the presence of 9α and 9β sequences [7,8]. GRα and
GRβ proteins are composed of 777 and 742 amino acids, respectively. They are identical from amino acid residue 1 to 727, and are dis-
tinct only in the carboxyl terminal region. GRβ does not contain helix 12 of carboxy terminus ligand-binding domain (LBD) but has a
different amino acid sequence in helix 11 compared to GRα. The shorter LBD of GRβ cannot bind ligand, and is not able to mediate anti-
inflammatory GCs effects [7,8]. 
Table 1. Demographic, organ system involvement of patients with
low and high disease activity (DA).
aAs defined by SLEDAI score index [2]. bregards low DA patients.
(5'AGC GGT TTT ATC AAC TGA C 3'), (5'TGA GTT CTA TTTT
TTG AGC G3') and (5'CTG GAG ACA GCA AGG TCG TCC -3'),
(5'CCA GCT TCT TGC TCA ATT CC3'), respectively. For ampli-
fication, 2 μl of total (20 μl) cDNA solution was added to 18 μl of
QuantiTect® SYBER® Green PCR Master Mix QIAGEN GmbH
(Hilden, Germany) and primers. Since the amplification efficiency
of target and references genes slightly differed, quantification of
copy number of these genes was respectively derived from a dif-
ferent standard curve for target and references genes. One RNA
sample of each preparation was processed without RT-reaction to
provide a negative control in subsequent PCR. RQ-PCR results
were expressed as copies per 1 μg of RNA.
Sodium dodecyl sulfate-polyacrylamide gel electrophoresis
(SDS-PAGE) and western blotting analysis of GRα and GRβ
proteins content in PBMCs. PBMCs were lysed in lysis buffer
and twenty micrograms of protein was resuspended in sample
buffer and separated on 10% Tris-glicyne gel using SDS-PAGE.
Gel proteins were transferred to nitrocellulose, which was blocked
with 3% milk in Tris buffered saline/Tween. Immunodetection was
performed with rabbit anti-GRα Ab, rabbit anti-GRβ Ab and HRP-
conjugated goat anti-rabbit Ab. The membranes were reblotted
with anti-actin HRP-conjugated Ab to equalize protein loading of
the lanes. Bands were revealed using ECL kit and Hyperfilm ECL
Amersham (Piscataway, NJ). The quantities of GRα and GRβ were
determined based on the band intensity in the autoradiogram.
Statistical analysis. Data groups were analyzed by ANOVA to
evaluate similarity between the groups (significant difference was
recognized at p<0.05). For all experimental groups, which satisfied
the initial ANOVA criteria, individual comparisons were done with
the use of post hoc Newman-Keul's test with the assumption of
two-tailed distribution and two samples with equal variance at the
p<0.05 level. 
Results and discussion
GCs are both naturally occurring and synthetic steroid
hormones that contribute to a wide spectrum of human
physiological processes and participate in the develop-
ment of many organs and systems [11-13]. GCs are
effective immunomodulatory and anti-inflammatory
agents in the treatment of autoimmune diseases and
some lymphoid malignancies [5,9]. 
We found that two patients with high SLE activity
exhibited elevated GRβ transcript and protein levels in
PBMCs (Table 1, Fig. 2). The average GRβ transcripts
and proteins amount in PBMCs of these two patients
was several times higher compared to patients with
low disease activity, respectively (Fig. 2). The levels of
expression of GRβ in low disease activity patients and
healthy individuals were similar (results not shown). 
Our findings suggest that increased expression of
GRβ in SLE patients may be associated with high dis-
ease activity. Previous studies have demonstrated that
GRβ could function as a dominant inhibitor of GRα
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Fig. 2. Levels of GRα and GRβ transcript (A) and protein (B) in PBMCs from SLE patients with low disease activity (P1-P10) and high
disease activity (P1HA, P2HA) PMBCs were used to isolate total RNA and proteins for RQ-PCR and western blotting analysis of GR vari-
ants. RQ-PCR results were standardized by POLR2A cDNA levels and were expressed as copies per 1 RNA μg. Results are representa-
tive of triplicate value means with SEM <15%; * p<0.05. For western blotting analysis, cell proteins were separated by SDS-PAGE and
transferred to a membrane that was then immunoblotted with rabbit polyclonal anti-GRα and anti-GRβ Abs, and secondary goat anti-rab-
bit HRP-conjugated Ab. To equalize protein loading we reblotted with anti-actin HRP-conjugated Ab. The GRβ amounts were determined
based on the band intensity in the autoradiogram.  A and B correspond to 94 and 91 KDa GRα isoforms, respectively.
erasing the anti-inflammatory effect of GCs in inflam-
matory cells [7,9]. Overexpression of GRβ in inflam-
matory cells was found in GC-resistant patients with
asthma, ulcerative colitis, nasal polyposis, Crohn's dis-
ease, and some lymphoid malignancies [9,14-16].
Lymphoblastic/lymphocytic leukemia patients with
high GRβ/GRα proteins ratio were also less sensitive
to the apoptosis induced by GC treatment [15,16]. 
We did not find sequence alterations in GR cDNA
and in DNA of 5'-regulatory region, nine exons, and
~300 bp of 3' region of the GR gene in PBMCs from
GC-resistant patients (result not shown). This finding
is consistent with those of Shahidi et al. [16], who
have not indicated sequence alterations in GR cDNA
and GR gene in a single case of GC-resistant chronic
lymphocytic leukemia [16]. 
Our preliminary report is the first to demonstrate a
possibility of association between increased expres-
sion of GRβ isoform and more severe manifestation of
SLE. This also supports the significance of GRβ
expression in the development of certain severe cases
of other autoimmune diseases. 
Increased expression of GRβ can be responsible
for glucocorticoid resistance and loss of immuno-
supresive effect of GCs. Recently we observed that
epigenetic modifiers trichostatin A, sodium butyrate,
and 5-aza-2'-deoxycytidine are able to cause a
decrease in GRβ expression, which can be of impor-
tance for treatment possibilities in patients with
increased expression of GRβ [17].
However, further investigations must be conducted
to confirm these findings and to determine a mecha-
nism of GR mRNA splicing regulation and the role of
post-transcriptional/translational regulation of GR
expression in increased productivity of GRβ expres-
sion in highly active SLE disease.
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